<unk> , sold under the brand name Rhopressa among others, is a medication for the treatment of glaucoma. In the United States, in December 2017, the Food and Drug Administration (FDA) approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension. The European Medicines Agency approved it in 2019 for the same uses under the brand name Rhokiinsa. The FDA considers it to be a first-in-class medication.
Netarsudil
Vosoritide
Ecallantide
Oprelvekin
Vagisil
Co-codaprin
Enarodustat
Lesinurad